| Literature DB >> 24725904 |
Anne M Nabukenya1, Joseph K B Matovu, Fred Wabwire-Mangen, Rhoda K Wanyenze, Fredrick Makumbi.
Abstract
BACKGROUND: Epilepsy is a devastating disorder that impacts on patients' quality of life, irrespective of use of anti epileptic drugs (AEDs). This study estimates the health-related quality of life (HRQOL) and its associated predictors among epilepsy patients receiving AEDs.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24725904 PMCID: PMC3999846 DOI: 10.1186/1477-7525-12-49
Source DB: PubMed Journal: Health Qual Life Outcomes ISSN: 1477-7525 Impact factor: 3.186
Demographics and clinical characteristics
| | ||||||
|---|---|---|---|---|---|---|
| | | | | | ||
| 15 – 19 | 23 | 30.7 | 24 | 24.0 | 47 | 26.9 |
| 20 – 24 | 23 | 30.7 | 30 | 30.0 | 53 | 30.3 |
| 25-29 | 8 | 10.7 | 21 | 21.0 | 29 | 16.6 |
| 30+ | 21 | 28.0 | 25 | 25.0 | 46 | 20.3 |
| | | | | | | |
| Male | 48 | 64.0 | 47 | 47.0 | 95 | 54.3 |
| Female | 27 | 36.0 | 53 | 53.0 | 80 | 45.7 |
| | | | | | ||
| Married | 8 | 10.7 | 14 | 14.0 | 22 | 12.6 |
| Separated | 4 | 5.3 | 14 | 14.0 | 18 | 10.3 |
| Never married | 63 | 84.0 | 72 | 72.0 | 135 | 77.1 |
| | | | | | ||
| None | 12 | 16.0 | 11 | 11.0 | 23 | 13.1 |
| Primary | 32 | 42.7 | 35 | 35.0 | 67 | 38.3 |
| Incomplete secondary | 22 | 29.3 | 42 | 42.0 | 64 | 36.6 |
| Complete secondary | 9 | 12.0 | 12 | 12.0 | 21 | 12 |
| | | | | | ||
| Generalized | 70 | 93.3 | 76 | 76.8 | 146 | 83.9 |
| Partial | 5 | 6.7 | 23 | 23.2 | 28 | 16.1 |
| | | | | | ||
| Mono therapy | 28 | 37.3 | 8 | 8.0 | 36 | 20.6 |
| Poly-therapy | 47 | 62.7 | 92 | 92.0 | 139 | 79.4 |
| | | | | | ||
| H/worker | 13 | 17.3 | 53 | 53.5 | 66 | 37.9 |
| Self-referral | 46 | 61.3 | 46 | 46.5 | 92 | 52.9 |
| Other | 16 | 21.3 | 0 | 0.0 | 16 | 9.2 |
| | | | | | ||
| 3-12 months | 19 | 25.3 | 47 | 47.0 | 66 | 37.7 |
| More than 12 months | 56 | 74.7 | 53 | 53.0 | 109 | 62.3 |
*For epilepsy type - data was missing for one participant.
Overall HRQOL and its subscale/components scores
| Overall HRQOL | 58.1 | 13.1 | 28.1 | 85.4 | 57.7 | 21.6 | 0.75 | 0.77 |
| | | | | | | | | |
| Psychological functioning | 64.8 | 17.0 | 20.0 | 97.5 | 65.0 | 23.4 | 0.78 | 0.76 |
| Emotional well-being | 48.6 | 31.2 | 0.0 | 100.0 | 44.3 | 45.0 | 0.90 | 0.87 |
| Physical functioning | 40.9 | 20.5 | 0.0 | 100.0 | 40.0 | 30.0 | 0.79 | 0.72 |
| Mental functioning | 59.5 | 20.1 | 15.8 | 91.7 | 58.3 | 34.0 | 0.87 | 0.84 |
| Social functioning | 61.1 | 25.2 | 5.0 | 100.0 | 58.0 | 42.0 | 0.75 | 0.77 |
| | | | | | | | | |
| Mood disturbance | 62.2 | 18.9 | 20.0 | 100.0 | 65.0 | 25.0 | | |
| Anxiety and depression | 67.4 | 20.2 | 13.3 | 100.0 | 73.3 | 20.0 | | |
| Medical side effects | 66.5 | 27.3 | 0.0 | 100.0 | 66.7 | 33.3 | | |
| Self-assessed QOL | 61.7 | 20.4 | 25.0 | 100.0 | 75.0 | 25.0 |
Multiple linear regression and partial correlations (R = 0.97) for overall HRQOL
| AED side effects | -0.24 | 0.180 | -1.34 | 0.18 | -0.02 |
| Therapy (Poly | -1.16 | 0.466 | -2.49 | 0.01 | -0.04 |
| Seizure frequency | -2.29 | 0.505 | -4.53 | 0.00 | -0.06 |
| 0.18 | 0.014 | 12.91 | 0.00 | 0.18 | |
| 0.08 | 0.007 | 12.11 | 0.00 | 0.17 | |
| 0.07 | 0.012 | 5.82 | 0.00 | 0.08 | |
| 0.27 | 0.012 | 22.13 | 0.00 | 0.31 | |
| 0.22 | 0.009 | 23.27 | 0.00 | 0.32 | |
| 14.93 | 1.596 | 9.35 | 0.00 |
*Adjusted for hospital site.
Multiple linear regressions beta - coefficients for potential factors associated with HRQOL and its subscale scores
| Age | 0.11 | 0.33 | 0.06 | -0.09 | 0.13 | 0.08 |
| 3.00 | 7.65 | -3.77 | 4.77 | 6.68 | 4.34* | |
| | | | | | | |
| Separated vs married | -3.55 | 2.51 | -0.81 | -0.68 | -8.27 | -3.25 |
| Not married vs married | -1.84 | -5.30 | -2.00 | -10.14* | -10.74* | -5.94* |
| | | | | | | |
| Primary education vs none | 3.15 | -2.37 | -4.59 | 10.04* | 14.96* | 6.14* |
| Incomplete secondary vs none | 5.79 | -4.44 | -5.25 | 16.02* | 25.02* | 9.63* |
| Complete secondary vs none | 2.45 | -9.38 | -4.44 | 10.24 | 26.07* | 7.97* |
| 1.10 | 6.82 | -5.77 | 5.44 | 8.38* | 3.12* | |
| -6.31* | -15.16* | 7.48* | 7.69* | -3.68 | -6.85* | |
| -3.56* | -4.63* | 4.65* | -4.20* | -3.53* | -2.65* | |
| -2.49 | 30.93* | 13.56* | 12.89* | 14.19* | 8.02* | |
| 74.12 | 4.75 | 18.81 | 41.86 | 15.45 | 40.76 |
*Indicates significance at 5% level with tests carried on variables that have been transformed to normal distribution.